Covered recipient · General Payments record
DAVID T RUBIN
Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$162,001.68
129 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $91,668.75 | 30 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $44,669.50 | 23 |
| Travel and Lodging | $16,114.54 | 31 |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $7,411.12 | 1 |
| Food and Beverage | $2,123.19 | 42 |
| Education | $14.58 | 2 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $58,028.69 | 34 |
| AbbVie, Inc. | $29,440.42 | 28 |
| Janssen Biotech, Inc. | $13,818.17 | 14 |
| Janssen Scientific Affairs, LLC | $13,764.28 | 8 |
| Celgene Corporation | $10,384.64 | 9 |
| Takeda Pharmaceuticals U.S.A., Inc. | $9,899.61 | 8 |
| Gilead Sciences, Inc. | $5,972.53 | 8 |
| Shire North American Group Inc | $4,375.00 | 2 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $4,253.15 | 5 |
| Allergan Inc. | $4,252.58 | 6 |
| Genentech, Inc. | $2,912.61 | 3 |
| E.R. Squibb & Sons, L.L.C. | $2,750.00 | 1 |
| Eli Lilly and Company | $1,450.00 | 1 |
| Ironwood Pharmaceuticals, Inc | $700.00 | 2 |
Page 3 of 3; records 101–129 of 129 matching records. This page contains 29 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
DAVID T RUBIN
NPI 1699838102 · CMS profile ID 348816
Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology
CHICAGO, IL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–129 of 129 matching records. This page contains 29 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1699838102?year=2019&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- DAVID T RUBIN, NPI 1699838102, CMS profile ID 348816. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–129 of 129 matching records. This page contains 29 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1699838102?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). DAVID T RUBIN, NPI 1699838102, CMS profile ID 348816. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–129 of 129 matching records. This page contains 29 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1699838102?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- DAVID T RUBIN, NPI 1699838102, CMS profile ID 348816, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–129 of 129 matching records. This page contains 29 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1699838102?year=2019&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
129 matching records · $162,001.68 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–129 of 129.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $78.03 | 03/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681880985 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $5,600.00 | 03/16/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681937777 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $204.00 | 03/16/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 682039169 | CMS |
| PFIZER INC. | $51.41 | 03/10/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672122646 | CMS |
| PFIZER INC. | $296.30 | 03/10/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672122649 | CMS |
| PFIZER INC. | $940.00 | 03/09/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672672660 | CMS |
| PFIZER INC. | $940.00 | 03/09/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672672667 | CMS |
| PFIZER INC. | $940.00 | 03/09/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672673481 | CMS |
| PFIZER INC. | $558.44 | 03/08/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672122641 | CMS |
| PFIZER INC. | $22.37 | 03/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672485405 | CMS |
| PFIZER INC. | $37.59 | 03/07/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672458013 | CMS |
| PFIZER INC. | $80.35 | 03/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672458017 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $35.00 | 03/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 700471629 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $3,995.00 | 03/06/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 700471631 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $140.00 | 03/06/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 700471633 | CMS |
| AbbVie, Inc. | $4,375.00 | 02/27/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647893689 | CMS |
| AbbVie, Inc. | $7.29 | 02/22/2019 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647893687 | CMS |
| AbbVie, Inc. | $18.71 | 02/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647893691 | CMS |
| AbbVie, Inc. | $460.94 | 02/22/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647893693 | CMS |
| PFIZER INC. | $940.00 | 02/09/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672672656 | CMS |
| PFIZER INC. | $940.00 | 02/09/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672672663 | CMS |
| PFIZER INC. | $940.00 | 02/09/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672673485 | CMS |
| PFIZER INC. | $940.00 | 02/09/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672673487 | CMS |
| PFIZER INC. | $940.00 | 02/09/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672673491 | CMS |
| Ironwood Pharmaceuticals, Inc | $350.00 | 02/07/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709209569 | CMS |
| Ironwood Pharmaceuticals, Inc | $350.00 | 02/07/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709209571 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $47.37 | 02/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 700471625 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $35.78 | 02/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 700471627 | CMS |
| E.R. Squibb & Sons, L.L.C. | $2,750.00 | 01/09/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651355685 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
- Merged CMS profile IDs
- 1316931, 348816
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $30,207.48 | 25 |
| PY2025 | Principal investigator | $281,123.23 | 21 |
| PY2024 | Recipient | $33,804.00 | 22 |
| PY2024 | Principal investigator | $355,338.89 | 9 |
| PY2023 | Recipient | $28,550.00 | 24 |
| PY2023 | Principal investigator | $66,066.53 | 21 |
| PY2022 | Recipient | $27,050.00 | 23 |
| PY2022 | Principal investigator | $110,484.43 | 47 |
| PY2021 | Recipient | $19,180.00 | 15 |
| PY2021 | Principal investigator | $174,613.07 | 47 |
| PY2020 | Recipient | $25,175.00 | 15 |
| PY2020 | Principal investigator | $351,574.99 | 88 |
| PY2019 | Principal investigator | $817,773.16 | 54 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
46 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Recipient | PFIZER INC. | $3,200.00 | 12/19/2025 | Covered Recipient Physician | TOFACITINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228727711 |
| Recipient | PFIZER INC. | $780.00 | 12/16/2025 | Covered Recipient Physician | TOFACITINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228727713 |
| Recipient | PFIZER INC. | $1,400.00 | 12/05/2025 | Covered Recipient Physician | ETRASIMOD CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228727103 |
| Recipient | ABBVIE INC. | $1,350.00 | 11/20/2025 | Covered Recipient Physician | Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease (Target CD) | No dispute reported | 06/30/2026 | 1202400997 |
| Recipient | PFIZER INC. | $330.00 | 11/17/2025 | Covered Recipient Physician | ETRASIMOD CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228723436 |
| Recipient | PFIZER INC. | $330.00 | 11/17/2025 | Covered Recipient Physician | ETRASIMOD CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228727423 |
| Recipient | PFIZER INC. | $330.00 | 11/17/2025 | Covered Recipient Physician | ETRASIMOD CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228727505 |
| Recipient | PFIZER INC. | $330.00 | 11/17/2025 | Covered Recipient Physician | ETRASIMOD CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228727661 |
| Recipient | PFIZER INC. | $330.00 | 11/14/2025 | Covered Recipient Physician | ETRASIMOD CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228727507 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $162,730.00 | 11/10/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF CHICAGO HOSPITALS | Longitudinal Changes of Patient Reported Outcomes and Quality of Life Measures in Inflammatory Bowel Disease PROMISE Study--Fitbit study --no compound | No dispute reported | 06/30/2026 | 1223271885 |
| Principal investigator 1 | Genentech, Inc. | $1,067.00 | 11/07/2025 | Non-covered Recipient Entity THE UNIVERSITY OF CHICAGO | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211669593 |
| Recipient | PFIZER INC. | $940.00 | 10/27/2025 | Covered Recipient Physician | ETRASIMOD CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228727659 |
| Recipient | PFIZER INC. | $940.00 | 10/26/2025 | Covered Recipient Physician | ETRASIMOD CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228727873 |
| Principal investigator 1 | Janssen Research & Development, LLC | $747.75 | 10/16/2025 | Non-covered Recipient Entity Univ Of Chicago | Long term Exposure Registry of Adult Patients With Moderate to Severe Ulcerative Colitis | No dispute reported | 06/30/2026 | 1175213365 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $25,272.00 | 10/10/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF CHICAGO HOSPITALS | ENTYVIO (VEDOLIZUMAB) LONG-TERM SAFETY STUDY: AN INTERNATIONAL OBSERVATIONAL PROSPECTIVE COHORT STUDY COMPARING VEDOLIZUMAB TO OTHER BIOLOGIC AGENTS IN PATIENTS WITH ULCERATIVE COLITIS OR CROHN'S DISEASE | No dispute reported | 06/30/2026 | 1223271883 |
| Principal investigator 1 | Genentech, Inc. | $1,412.00 | 10/09/2025 | Non-covered Recipient Entity THE UNIVERSITY OF CHICAGO | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211669590 |
| Recipient | PFIZER INC. | $780.00 | 10/02/2025 | Covered Recipient Physician | TOFACITINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228727503 |
| Recipient | PFIZER INC. | $1,400.00 | 09/25/2025 | Covered Recipient Physician | ETRASIMOD CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228727871 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,147.00 | 09/12/2025 | Non-covered Recipient Entity THE UNIVERSITY OF CHICAGO | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211669562 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $2,276.00 | 08/26/2025 | Non-covered Recipient Entity THE UNIVERSITY OF CHICAGO | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211669559 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $4,080.00 | 08/14/2025 | Non-covered Recipient Entity THE UNIVERSITY OF CHICAGO | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211669555 |
| Principal investigator 1 | Genentech, Inc. | $3,900.00 | 08/01/2025 | Non-covered Recipient Entity THE UNIVERSITY OF CHICAGO | vixarelimab ulcerative colitis study | No dispute reported | 06/30/2026 | 1211669625 |
| Principal investigator 1 | Genentech, Inc. | $3,900.00 | 08/01/2025 | Non-covered Recipient Entity THE UNIVERSITY OF CHICAGO | vixarelimab ulcerative colitis study | No dispute reported | 06/30/2026 | 1211669629 |
| Principal investigator 1 | Genentech, Inc. | $25,350.00 | 08/01/2025 | Non-covered Recipient Entity THE UNIVERSITY OF CHICAGO | vixarelimab ulcerative colitis study | No dispute reported | 06/30/2026 | 1211669632 |
| Recipient | PFIZER INC. | $3,200.00 | 07/24/2025 | Covered Recipient Physician | TOFACITINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228727869 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,495.50 | 07/22/2025 | Non-covered Recipient Entity Univ Of Chicago | Long term Exposure Registry of Adult Patients With Moderate to Severe Ulcerative Colitis | No dispute reported | 06/30/2026 | 1175212651 |
| Principal investigator 1 | Genentech, Inc. | $1,924.00 | 06/19/2025 | Non-covered Recipient Entity THE UNIVERSITY OF CHICAGO | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211669576 |
| Principal investigator 1 | Genentech, Inc. | $14,950.00 | 06/05/2025 | Non-covered Recipient Entity THE UNIVERSITY OF CHICAGO | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211669567 |
| Principal investigator 1 | Genentech, Inc. | $3,900.00 | 06/05/2025 | Non-covered Recipient Entity THE UNIVERSITY OF CHICAGO | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211669572 |
| Principal investigator 1 | Genentech, Inc. | $4,634.00 | 06/05/2025 | Non-covered Recipient Entity THE UNIVERSITY OF CHICAGO | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211669579 |
| Principal investigator 1 | Genentech, Inc. | $10,400.00 | 06/05/2025 | Non-covered Recipient Entity THE UNIVERSITY OF CHICAGO | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211669581 |
| Principal investigator 1 | Genentech, Inc. | $3,900.00 | 06/05/2025 | Non-covered Recipient Entity THE UNIVERSITY OF CHICAGO | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211669586 |
| Recipient | PFIZER INC. | $330.00 | 06/02/2025 | Covered Recipient Physician | ETRASIMOD CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228768599 |
| Recipient | PFIZER INC. | $3,200.00 | 05/29/2025 | Covered Recipient Physician | ETRASIMOD CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228760742 |
| Recipient | PFIZER INC. | $3,200.00 | 05/29/2025 | Covered Recipient Physician | ETRASIMOD CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228761026 |
| Recipient | ABBVIE INC. | $47.48 | 05/06/2025 | Covered Recipient Physician | A Phase 2a Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderate to Severe Crohn's Disease | No dispute reported | 06/30/2026 | 1202400989 |
| Recipient | ABBVIE INC. | $2,700.00 | 05/06/2025 | Covered Recipient Physician | A Phase 2a Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderate to Severe Crohn's Disease | No dispute reported | 06/30/2026 | 1202400993 |
| Recipient | PFIZER INC. | $940.00 | 05/05/2025 | Covered Recipient Physician | ETRASIMOD CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228768733 |
| Recipient | PFIZER INC. | $330.00 | 04/24/2025 | Covered Recipient Physician | ETRASIMOD CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228724824 |
| Recipient | PFIZER INC. | $330.00 | 04/24/2025 | Covered Recipient Physician | ETRASIMOD CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228770912 |
| Principal investigator 1 | Janssen Research & Development, LLC | $747.75 | 04/03/2025 | Non-covered Recipient Entity Univ Of Chicago | Long term Exposure Registry of Adult Patients With Moderate to Severe Ulcerative Colitis | No dispute reported | 06/30/2026 | 1175213392 |
| Principal investigator 1 | ABBVIE INC. | $2,825.00 | 03/27/2025 | Non-covered Recipient Entity UNIVERSITY OF CHICAGO | M14-533 - A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | No dispute reported | 06/30/2026 | 1202466918 |
| Recipient | PFIZER INC. | $940.00 | 02/21/2025 | Covered Recipient Physician | ETRASIMOD CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228768255 |
| Recipient | PFIZER INC. | $940.00 | 02/20/2025 | Covered Recipient Physician | ETRASIMOD CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228770289 |
| Principal investigator 1 | ABBVIE INC. | $4,465.23 | 01/07/2025 | Non-covered Recipient Entity THE UNIVERSITY OF CHICAGO | A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn Disease (CD) | No dispute reported | 06/30/2026 | 1202437085 |
| Recipient | Genentech, Inc. | $1,610.00 | 01/02/2025 | Covered Recipient Physician | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211535342 |